Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2012-07-30

2012

Ντικούδη Ευαγγελία

Κωνσταντίνος Ν. Συρίγος Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας ΕΚΠΑ, Ανδριανή Χαρπίδου Επιστημονική Συνεργάτης Ιατρικής Σχολής ΕΚΠΑ, Αδάμ Αδαμόπουλος Επικ. Καθηγητής Γαστρεντερολογίας ΕΚΠΑ

Επίπεδα λεπτίνης στο BAL και στον ορό ασθενών με Καρκίνο Πνεύμονα

Greek

Introduction
Leptin is a pleotropic hormone, member of the adipocytokines, secretory
products of adipose tissue. Leptin has been studied in obesity- related cancer.
Additionally leptin has been studied as a cancer cachexia mediator.
Purpose
The aim of this study was to summarize data that concerned leptin and lung
cancer pathogenesis, prognosis and lung cancer cachexia.
Materials & Methods
A systematic literature search was performed in electronic databases of Medline
and Embase.
Results
In vitro leptin acts as a growth factor for lung cancer. Single Nucleotide
Polymorphisms of leptin or leptin receptor gene represent independent risk
factors for lung cancer along with elevated serum or lung tissue leptin levels.
Leptin serum levels however among lung cancer cachectic patients are found low
in proportion to diminished fat mass. Therefore, leptin mediates neither
anorexia nor the systemic inflammation of cancer cachexia.
Conclusions
The double system of leptin/leptin receptor is essential for lung cancer
development, increases risk for lung cancer and affects its prognosis
negatively. Moreover leptin represents a useful nutritional marker, especially
in advanced lung cancer stages. Future studies are warranted to elucidate
leptin’s role in lung cancer in order to improve survival and to unravel leptin
as a therapeutic target as well.

Leptin, Lung cancer, Pathogenesis, Survival, Cachexia

No

0

Yes

252

169

File access is restricted.

https://pergamos.lib.uoa.gr/uoa/dl/object/1311305